Press Releases

Press Releases

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

As of the March 11, 2022 data cut-off date, 16 patients in 7 dosing cohorts with different types of progressing cancer received ANV419 every 14 days. ANV419, administered intravenously over 15 minutes was exceptionally well tolerated with most patients experiencing a mild Grade 1 infusion-related reaction with chills and low-grade fever a few hours after dosing, which resolved with antipyretic treatment. No patients experienced a Grade 3 or worse drug related AE and no patients have withdrawn from study due to AEs. No dose limiting toxicities have been observed.
read more